Sonosemi Medical, the Shenzhen-based National High-Tech Enterprise pioneering active vascular interventional diagnosis and treatment solutions, has secured a significant $100.0M in Series B funding. The round drew investment from a notable group including Tencent Investment, Eight Roads (斯道资本), Yahui Investment (雅惠投资), and Yuexiu Industrial Fund (越秀产业基金), alongside CCB Equity (建信股权), Cornerstone Capital (基石资本), Furong Investment (复容投资), Ruijian Capital (睿笕资本), and Jiuzhixinfei (久知心飞).
Founded in April 2020, Sonosemi Medical has quickly established itself as a leading provider in China, committed to delivering greener, more precise, and safer medical solutions. Its product lineup features advanced systems like the Coronary Intravascular Lithotripsy System and Intracardiac Echocardiography System.


















